In vitro study on the feasibility of magnetic stent hyperthermia for the treatment of cardiovascular restenosis

Li, Li; Wang, Rui; Shi, Huan‑Huan; Xie, Le; Li, Jingdingsha; Kong, Weichao; Tang, Jintian; Ke, Da‐Nian; Zhao, Lingyun

doi:10.3892/etm.2013.1177

Cited by 17 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be due to the improved cardiovascular tolerance associated with this renal replacement therapy method. This method presents episodes of hypotension (and consequently renal ischemia), and to be a lower level of activation of the inflammatory pathway, since the blood is not in contact with artificial membranes (11)(12)(13). PD is particularly suitable for patients with refractory heart failure or hemodynamically instable conditions where systemic anticoagulation should be avoided.…”

Section: Discussionmentioning

confidence: 99%

Peritoneal dialysis treatment for severe lupus nephritis patients complicated with essential organ dysfunction

Zhou

Tang

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The aim of the present study was to evaluate the clinical efficacy of peritoneal dialysis (PD) in patients with severe lupus nephritis (LN) complicated with organ dysfunction. In total, 13 severe LN patients complicated with multiple-organ dysfunction, who underwent PD treatment between November 2003 and September 2010, were enrolled in the study. Six patients received methylprednisolone pulse therapy due to lupus activity and progressive renal failure. These patients were complicated with severe edema, cardiac insufficiency and severe hypoalbuminemia. PD was applied to the patients, followed by the administration of immunosuppressants. Patients were followed-up to review the parameters of renal function, the immunological indexes and the systemic lupus erythematosus disease activity index. The results indicated that the general state of health was markedly improved following PD treatment, with edema abatement and improvement of heart function and physical strength. Serum creatinine levels significantly decreased from 6.3±1.6 to 2.6±1.0 mg/dl. A total of 10 cases ceased PD treatment during the follow-up, while three cases continued PD to the end of the follow-up period. The levels of albumin and hemoglobin exhibited a marked increase from 29.7±5.7 to 35.2±5.5 g/l and 8.7±1.8 to 9.8±1.8 g/l, respectively. There was one case of peritonitis, one case of peritoneal leakage and two cases of pneumonia. Therefore, PD may be a successful treatment method for severe LN patients complicated with essential organ dysfunction. PD not only improved the symptoms of edema and heart failure, but also played an important role in preserving residual renal function and improving the nutritional state of the patients. Thus, PD can be considered as a treatment option for patients with severe LN associated with acute kidney injury, however, selecting a suitable immunosuppressant during PD treatment is essential.

show abstract

Section: Discussionmentioning

confidence: 99%

Peritoneal dialysis treatment for severe lupus nephritis patients complicated with essential organ dysfunction

Zhou

Tang

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Higher power levels of some 1–10 KW were applied to initiate inductive heating [ 99 , 100 ], which is neither safe nor practical in clinical applications.…”

Section: In-stent Restenosis Treatmentmentioning

confidence: 99%

Health Care Monitoring and Treatment for Coronary Artery Diseases: Challenges and Issues

Alghrairi

Sulaiman

Mutashar

2020

Sensors

View full text Add to dashboard Cite

In-stent restenosis concerning the coronary artery refers to the blood clotting-caused re-narrowing of the blocked section of the artery, which is opened using a stent. The failure rate for stents is in the range of 10% to 15%, where they do not remain open, thereby leading to about 40% of the patients with stent implantations requiring repeat procedure within one year, despite increased risk factors and the administration of expensive medicines. Hence, today stent restenosis is a significant cause of deaths globally. Monitoring and treatment matter a lot when it comes to early diagnosis and treatment. A review of the present stent monitoring technology as well as the practical treatment for addressing stent restenosis was conducted. The problems and challenges associated with current stent monitoring technology were illustrated, along with its typical applications. Brief suggestions were given and the progress of stent implants was discussed. It was revealed that prime requisites are needed to achieve good quality implanted stent devices in terms of their size, reliability, etc. This review would positively prompt researchers to augment their efforts towards the expansion of healthcare systems. Lastly, the challenges and concerns associated with nurturing a healthcare system were deliberated with meaningful evaluations.

show abstract

“…VSMCs are typically found in a quiescent state as well-differentiated cells with a functional contractile apparatus, requiring little protein turnover [ 5 ]. However, in pathological situations such as stent induced stress their molecular mechanisms are triggered, and VSMCs thereby transform into cells with a high proliferative and migratory capacity that secrete extracellular matrix proteins [ 6 ]. This phenotypic switch is the therapeutic target of DES via drugs that inhibit the cell cycle to control the expansion of VSMCs and the formation of neo-intima [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Long Non-Coding RNAs Might Regulate Phenotypic Switch of Vascular Smooth Muscle Cells Acting as ceRNA: Implications for In-Stent Restenosis

Arencibia

Lanas

Salazar

2022

IJMS

View full text Add to dashboard Cite

Coronary in-stent restenosis is a late complication of angioplasty. It is a multifactorial process that involves vascular smooth muscle cells (VSMCs), endothelial cells, and inflammatory and genetic factors. In this study, the transcriptomic landscape of VSMCs’ phenotypic switch process was assessed under stimuli resembling stent injury. Co-cultured contractile VSMCs and endothelial cells were exposed to a bare metal stent and platelet-derived growth factor (PDGF-BB) 20 ng/mL. Migratory capacity (wound healing assay), proliferative capacity, and cell cycle analysis of the VSMCs were performed. RNAseq analysis of contractile vs. proliferative VSMCs was performed. Gene differential expression (DE), identification of new long non-coding RNA candidates (lncRNAs), gene ontology (GO), and pathway enrichment (KEGG) were analyzed. A competing endogenous RNA network was constructed, and significant lncRNA–miRNA–mRNA axes were selected. VSMCs exposed to “stent injury” conditions showed morphologic changes, with proliferative and migratory capacities progressing from G0-G1 cell cycle phase to S and G2-M. RNAseq analysis showed DE of 1099, 509 and 64 differentially expressed mRNAs, lncRNAs, and miRNAs, respectively. GO analysis of DE genes showed significant enrichment in collagen and extracellular matrix organization, regulation of smooth muscle cell proliferation, and collagen biosynthetic process. The main upregulated nodes in the lncRNA-mediated ceRNA network were PVT1 and HIF1-AS2, with downregulation of ACTA2-AS1 and MIR663AHG. The PVT1 ceRNA axis appears to be an attractive target for in-stent restenosis diagnosis and treatment.

show abstract

In vitro study on the feasibility of magnetic stent hyperthermia for the treatment of cardiovascular restenosis

Cited by 17 publications

References 25 publications

Peritoneal dialysis treatment for severe lupus nephritis patients complicated with essential organ dysfunction

Peritoneal dialysis treatment for severe lupus nephritis patients complicated with essential organ dysfunction

Health Care Monitoring and Treatment for Coronary Artery Diseases: Challenges and Issues

Long Non-Coding RNAs Might Regulate Phenotypic Switch of Vascular Smooth Muscle Cells Acting as ceRNA: Implications for In-Stent Restenosis

Contact Info

Product

Resources

About